BCR and non-small cell lung carcinoma: For example, Tyrosine kinase inhibitors such as imatinib, bosutinib, and dasatinib targeting the BCR-ABL fusion protein have improved outcomes in Philadelphia chromosome positive leukemia1, and similar approaches have made a considerable impact in breast cancer2, non-small cell lung cancer (NSCLC)3, and several other cancer types.